7 results
Summary of dosing recommendations in renal impairment of commonly used hypoglycaemic agents

#Diabetes #Diabetic #Medications #Pharmacology #Dosing
Summary of dosing ... #Diabetic #Medications ... #Pharmacology # ... Renal #Impairment #CKD ... #Table #GFR #Hypoglycemics
Summary of Non-Insulin Agents Used to Treat Diabetes

#Diabetes #Pharmacology #Comparison #Table #Medications #Noninsulin #Orals #Agents
Summary of Non-Insulin ... Used to Treat Diabetes ... #Diabetes #Pharmacology ... #Comparison #Table
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... Insulin Lifestyle ... Improved outcomes in CKD ... #medications #table
Sulfonylureas - Pharmacology Summary
Mechanisms of Action: Binds to the ATP-sensitive potassium channel in pancreatic beta cells,
Sulfonylureas - Pharmacology ... Summary Mechanisms ... cells, triggering insulin ... contraindicated in CKD ... diabetes #endocrinology
Management of Diabetes Mellitus in Patients With CKD

1. Monitor for changes in BP, serum creatinine, &
ADA/KDIGO Consensus ... evidence-based pharmacologic ... #Diabetes #CKD # ... ADA #KDIGO #eGFR ... #Insulin #metformin
Estimating the Total Daily Dose (TDD) of Insulin: Weight-Based Dosing
TDD in units of insulin = N
(stage IV or V CKD ... including most 2 diabetics ... Add sliding scale ... Weight #Based #pharmacology ... endocrinology #diabetes
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... Summary Mechanisms ... glucose-dependent insulin ... Ozempic), or daily tablet ... diabetes #endocrinology